Keynote-689 Trial Finds Pembrolizumab Doubles Disease-Free Survival in Head and Neck Cancer

Presented at the American Society of Clinical Oncology meeting, the global study offers regulators data on pembrolizumab’s performance following its demonstration of five-year remission with reduced metastatic risk.